IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.914
AS - Asia 7.595
EU - Europa 7.040
SA - Sud America 1.197
AF - Africa 395
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.152
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.702
SG - Singapore 3.085
CN - Cina 2.666
IT - Italia 1.295
FI - Finlandia 1.149
IE - Irlanda 1.132
BR - Brasile 991
SE - Svezia 984
DE - Germania 764
HK - Hong Kong 586
UA - Ucraina 541
VN - Vietnam 403
NL - Olanda 291
TR - Turchia 279
ZA - Sudafrica 253
GB - Regno Unito 192
IN - India 156
RU - Federazione Russa 155
CA - Canada 148
FR - Francia 133
AT - Austria 97
AR - Argentina 86
BE - Belgio 84
CI - Costa d'Avorio 71
BD - Bangladesh 56
KR - Corea 54
PL - Polonia 54
JP - Giappone 45
MX - Messico 44
ID - Indonesia 42
EC - Ecuador 40
CZ - Repubblica Ceca 37
ES - Italia 37
IQ - Iraq 33
CO - Colombia 25
IR - Iran 23
PK - Pakistan 23
LT - Lituania 21
MA - Marocco 19
UZ - Uzbekistan 19
VE - Venezuela 18
PS - Palestinian Territory 14
TN - Tunisia 14
JO - Giordania 13
EE - Estonia 12
EG - Egitto 12
AE - Emirati Arabi Uniti 10
AZ - Azerbaigian 10
PY - Paraguay 10
IL - Israele 9
KE - Kenya 9
PE - Perù 9
HU - Ungheria 8
RO - Romania 8
AL - Albania 7
KZ - Kazakistan 7
UY - Uruguay 7
CL - Cile 6
DZ - Algeria 6
KG - Kirghizistan 6
LB - Libano 6
LU - Lussemburgo 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
JM - Giamaica 5
QA - Qatar 5
BO - Bolivia 4
CR - Costa Rica 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
AM - Armenia 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
EU - Europa 3
GE - Georgia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
NO - Norvegia 3
OM - Oman 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
HN - Honduras 2
MY - Malesia 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
Totale 26.137
Salva come PNG Salva come JPEG
Città #
Singapore 1.542
Dublin 1.130
Chandler 1.092
Ashburn 1.029
Dallas 1.008
Santa Clara 670
Beijing 661
Jacksonville 613
Ann Arbor 597
Hong Kong 581
Dearborn 447
Parma 435
Boardman 329
Nanjing 264
New York 256
Izmir 243
Johannesburg 241
Shanghai 227
Princeton 210
Munich 207
Los Angeles 204
San Mateo 178
Hefei 165
Ho Chi Minh City 144
Wilmington 138
Bremen 128
Helsinki 113
Milan 98
Nanchang 98
São Paulo 98
Kunming 93
Shenyang 92
Chicago 87
Hebei 85
Toronto 85
Moscow 83
Vienna 82
Jinan 81
Hanoi 79
Buffalo 78
Woodbridge 72
Abidjan 71
Brussels 67
Tianjin 64
Columbus 58
Des Moines 55
Seattle 53
Guangzhou 50
Seoul 50
Changsha 49
Marseille 49
Turku 49
Houston 46
Jiaxing 46
Bologna 40
Pune 39
Warsaw 38
London 37
The Dalles 37
Tokyo 37
Brooklyn 36
Frankfurt am Main 36
Norwalk 35
Rio de Janeiro 34
Amsterdam 33
Düsseldorf 32
Modena 32
Rome 32
Jakarta 31
Council Bluffs 27
Stockholm 27
Belo Horizonte 25
Brasília 25
Denver 25
Hangzhou 25
Redmond 24
Reggio Emilia 24
Augusta 23
Fremont 23
Phoenix 23
Zhengzhou 23
San Francisco 22
Montreal 21
Leawood 20
Manchester 20
Poplar 20
Boston 19
Haiphong 19
Nuremberg 19
Brno 18
Chennai 18
Tashkent 18
Campinas 17
Curitiba 17
Wuhan 17
Wayne 16
Charlotte 15
Redondo Beach 15
Ardabil 14
Dong Ket 14
Totale 15.932
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 308
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 225
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 218
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 205
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 203
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 201
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 189
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 183
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 180
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 179
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 177
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 165
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 163
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 162
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 162
Characterization of gefitinib uptake in NSCLC cell lines 161
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 161
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 160
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 157
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 154
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 154
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 154
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 153
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 151
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 151
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 151
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 150
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 148
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 147
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 147
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 147
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 146
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 146
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 146
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 144
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 144
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 143
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 143
5-benzylidene-hydantoins as new inhibitors of cell proliferation 142
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 142
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 141
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 139
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 139
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 138
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 138
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 138
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 136
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 135
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 134
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 133
An original application of plasma expanders: heart-lung preservation. 133
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 131
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 131
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 131
Adaptive cellular response to osmotic stress in pig articular chondrocytes 131
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 131
Induction of betaine/gammabutyric acid transport activity in chondrocytes exposed to hypertonicity 130
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 130
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 129
New MDR1 inhibitors for overcoming multidrug resistance 129
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 129
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 129
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 129
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 128
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 128
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 128
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 128
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 127
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 127
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 127
SiO2/SiC core-shell nanowires for nanomedicine applications 127
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 126
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 126
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 126
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 126
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 125
Mannich base derivatives as novel EGFR irreversible inhibitors 124
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 123
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 123
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 121
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 121
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 121
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 120
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 120
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 120
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 119
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 118
Totale 14.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021969 0 0 0 0 0 52 148 64 277 55 312 61
2021/20221.057 49 33 48 65 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.843 88 141 59 50 151 456 133 141 65 96 160 303
2024/20255.752 190 298 368 406 555 618 313 236 778 500 510 980
2025/20266.625 1.111 1.163 1.531 1.111 1.610 99 0 0 0 0 0 0
Totale 26.466